Works matching IS 1742464X AND DT 2021 AND VI 288 AND IP 21
Results: 16
In Conversation with Tony Letai.
- Published in:
- FEBS Journal, 2021, v. 288, n. 21, p. 6087, doi. 10.1111/febs.16229
- By:
- Publication type:
- Article
The ever‐expanding landscape of cancer therapeutic approaches.
- Published in:
- FEBS Journal, 2021, v. 288, n. 21, p. 6082, doi. 10.1111/febs.16228
- Publication type:
- Article
Calcium signaling in cancer progression and therapy.
- Published in:
- FEBS Journal, 2021, v. 288, n. 21, p. 6187, doi. 10.1111/febs.16133
- By:
- Publication type:
- Article
Quantitative imaging and dynamics of tumor therapy with viruses.
- Published in:
- FEBS Journal, 2021, v. 288, n. 21, p. 6273, doi. 10.1111/febs.16102
- By:
- Publication type:
- Article
Oncogenic dysregulation of pre‐mRNA processing by protein kinases: challenges and therapeutic opportunities.
- Published in:
- FEBS Journal, 2021, v. 288, n. 21, p. 6250, doi. 10.1111/febs.16057
- By:
- Publication type:
- Article
Development of new therapeutic options for the treatment of uveal melanoma.
- Published in:
- FEBS Journal, 2021, v. 288, n. 21, p. 6226, doi. 10.1111/febs.15869
- By:
- Publication type:
- Article
Role of the runt‐related transcription factor (RUNX) family in prostate cancer.
- Published in:
- FEBS Journal, 2021, v. 288, n. 21, p. 6112, doi. 10.1111/febs.15804
- By:
- Publication type:
- Article
Druggable genome and precision medicine in cancer: current challenges.
- Published in:
- FEBS Journal, 2021, v. 288, n. 21, p. 6142, doi. 10.1111/febs.15788
- By:
- Publication type:
- Article
Engineering soluble T‐cell receptors for therapy.
- Published in:
- FEBS Journal, 2021, v. 288, n. 21, p. 6159, doi. 10.1111/febs.15780
- By:
- Publication type:
- Article
Pediatric high‐grade glioma: moving toward subtype‐specific multimodal therapy.
- Published in:
- FEBS Journal, 2021, v. 288, n. 21, p. 6127, doi. 10.1111/febs.15739
- By:
- Publication type:
- Article
Tumor‐associated macrophages in immunotherapy.
- Published in:
- FEBS Journal, 2021, v. 288, n. 21, p. 6174, doi. 10.1111/febs.15726
- By:
- Publication type:
- Article
Tools to study and target the Siglec–sialic acid axis in cancer.
- Published in:
- FEBS Journal, 2021, v. 288, n. 21, p. 6206, doi. 10.1111/febs.15647
- By:
- Publication type:
- Article
Targeting dormant tumor cells to prevent cancer recurrence.
- Published in:
- FEBS Journal, 2021, v. 288, n. 21, p. 6286, doi. 10.1111/febs.15626
- By:
- Publication type:
- Article
New insights into the activities and toxicities of the old anticancer drug doxorubicin.
- Published in:
- FEBS Journal, 2021, v. 288, n. 21, p. 6095, doi. 10.1111/febs.15583
- By:
- Publication type:
- Article
Table of Contents.
- Published in:
- FEBS Journal, 2021, v. 288, n. 21, p. 6304, doi. 10.1111/febs.15417
- Publication type:
- Article
Issue Information.
- Published in:
- FEBS Journal, 2021, v. 288, n. 21, p. 6079, doi. 10.1111/febs.15416
- Publication type:
- Article